Anti-LDLR/ LDL-R/ FH monoclonal antibody

Anti-LDLR/ LDL-R/ FH antibody for FACS & in-vivo assay

Target products collectionGo to LDL-R/LDLR products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T94692-Ab-1/ GM-Tg-hg-T94692-Ab-2Anti-Human LDL-R/LDLR monoclonal antibodyHuman
GM-Tg-rg-T94692-Ab-1/ GM-Tg-rg-T94692-Ab-2Anti-Rat LDL-R/LDLR monoclonal antibodyRat
GM-Tg-mg-T94692-Ab-1/ GM-Tg-mg-T94692-Ab-2Anti-Mouse LDL-R/LDLR monoclonal antibodyMouse
GM-Tg-cynog-T94692-Ab-1/ GM-Tg-cynog-T94692-Ab-2Anti-Cynomolgus/ Rhesus macaque LDL-R/LDLR monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T94692-Ab-1/ GM-Tg-felg-T94692-Ab-2Anti-Feline LDL-R/LDLR monoclonal antibodyFeline
GM-Tg-cang-T94692-Ab-1/ GM-Tg-cang-T94692-Ab-2Anti-Canine LDL-R/LDLR monoclonal antibodyCanine
GM-Tg-bovg-T94692-Ab-1/ GM-Tg-bovg-T94692-Ab-2Anti-Bovine LDL-R/LDLR monoclonal antibodyBovine
GM-Tg-equg-T94692-Ab-1/ GM-Tg-equg-T94692-Ab-2Anti-Equine LDL-R/LDLR monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg

Product Description

Catalog No.GM-Tg-hg-T94692-Ab-1/ GM-Tg-hg-T94692-Ab-2; GM-Tg-rg-T94692-Ab-1/ GM-Tg-rg-T94692-Ab-2;
GM-Tg-mg-T94692-Ab-1/ GM-Tg-mg-T94692-Ab-2; GM-Tg-cynog-T94692-Ab-1/ GM-Tg-cynog-T94692-Ab-2;
GM-Tg-felg-T94692-Ab-1/ GM-Tg-felg-T94692-Ab-2; GM-Tg-cang-T94692-Ab-1/ GM-Tg-cang-T94692-Ab-2;
GM-Tg-bovg-T94692-Ab-1/ GM-Tg-bovg-T94692-Ab-2; GM-Tg-equg-T94692-Ab-1/ GM-Tg-equg-T94692-Ab-2
Products NameAnti-LDL-R/LDLR monoclonal antibody
Target NameLDL-R
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
Products descriptionPre-made anti-LDL-R benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


    Data / case study

    Click to get more Data / Case study about the product.

    Associated products

    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-T94692-Ag-1Multi-species LDLR/ LDL-R/ FH VLP (virus-like particle)
    ORF Viral VectorvGMLP005154human LDLR Lentivirus particle
    ORF Viral VectorpGMLP005154human LDLR Lentivirus plasmid

    Target information

    Target IDGM-T94692
    Target NameLDL-R
    Gene ID3949,16835,300438,574283,100683160,101080362,281276,100057389
    Gene Symbol and SynonymsFH,FHC,FHCL1,Hlb301,LDLCQ2,LDLR,LDLRA
    Uniprot AccessionP01130,P35952,P01131
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    Gene EnsemblENSG00000130164
    Target ClassificationTumor-associated antigen (TAA)

    The target: LDL-R, gene name: LDLR, also named as FH, FHC, LDLCQ2. The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. The encoded protein is normally bound at the cell membrane, where it binds low density lipoprotein/cholesterol and is taken into the cell. Lysosomes release the cholesterol, which is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.[provided by RefSeq, May 2022].

    About Gmab

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s TaurusTM and LIBRATM platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.